维奈托克治疗淋巴恶性肿瘤：新的认识，更多的探索。
Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.
机构信息
The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia.
The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, 305 Grattan Street, Melbourne, VIC 3000, Australia; Department of Medical Biology and Centre for Cancer Research, University of Melbourne, Melbourne, VIC 3000, Australia; Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, VIC 3000, Australia.
出版信息
Cancer Cell. 2019 Oct 14;36(4):341-343. doi: 10.1016/j.ccell.2019.09.008.
In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.
在本期《癌细胞》杂志中，Guièza 等人描述了抗凋亡蛋白 MCL1 的过表达和细胞能量代谢重编程可导致慢性淋巴细胞白血病患者对 BCL2 抑制剂 venetoclax 产生耐药性。这为理解 venetoclax 的继发性临床耐药性增加了一个新的维度。
Zotero 插件